Study guide
14.2 Component Therapy
Specialist in Blood Banking, SBB ASCP
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility Routes & Credential Maintenance 1.3 Study Strategy for SBB
2 Donors & Collection
2.1 Donor Qualification 2.2 Collection Methods & Adverse Reactions 2.3 Special Donations
3 Processing, Storage & Component QC
3.1 Processing, Testing & Labeling 3.2 Storage, Transport & Expiration 3.3 Blood Component Quality Control
4 Red Cell & Modified Components
4.1 Whole Blood & Red Blood Cells 4.2 Leukocyte-Reduced, Washed, Frozen & Rejuvenated RBCs 4.3 Irradiated Components 4.4 Granulocytes
5 Platelets, Plasma & Cellular Products
5.1 Platelets 5.2 Plasma & Cryoprecipitated AHF 5.3 Apheresis Products & Fractionation Products 5.4 Hematopoietic Progenitors
6 Genetics, ABO & Rh
6.1 Blood Group Genetics & Molecular Inheritance 6.2 ABO & Lewis Systems 6.3 Rh System 6.4 MNS, P1PK/Globoside & Ii
7 Other Blood Groups & Role in Transfusion
7.1 Kell, Kidd, Duffy & Lutheran 7.2 Other Systems & High/Low-Prevalence Antigens 7.3 HLA, Platelet-Specific & Granulocyte Antigens 7.4 Immunogenicity & Antigen Prevalence
8 Immunology Foundations
8.1 Immune Response 8.2 Immunoglobulins 8.3 Antigen-Antibody Interactions 8.4 Complement
9 Physiology, Hemostasis & HDFN
9.1 Physiology of Blood 9.2 Hemostasis and Coagulation 9.3 HDFN Pathophysiology & Detection 9.4 HDFN Treatment & Prevention
10 Cytopenias & Transplantation
10.1 Immune & Nonimmune Anemia 10.2 Thrombocytopenia & Neutropenia 10.3 Solid Organ Transplantation Support 10.4 Hematopoietic Progenitor Cell Transplantation
11 Routine Serologic Testing
11.1 Blood Grouping Tests 11.2 Antibody Detection & Crossmatch 11.3 Antibody Identification & Clinical Significance 11.4 Direct Antiglobulin Testing & Reagents
12 Special Serologic Methods
12.1 Enzymes, Enhancement Media & Lectins 12.2 Adsorptions, Elutions & Titrations 12.3 Cell Separations, Neutralization & Thiol Reagents 12.4 Chloroquine Diphosphate & EDTA-Glycine Acid
13 Molecular Platforms & Serologic QA
13.1 Molecular Blood Group Techniques 13.2 ELISA, Immunofluorescence, Solid Phase & Column Agglutination 13.3 Serologic Quality Assurance
14 Indications, Component Therapy & PBM
14.1 Indications for Transfusion 14.2 Component Therapy 14.3 Blood Administration & Patient Blood Management
15 Adverse Effects of Transfusion
15.1 Immunologic Transfusion Reactions 15.2 Nonimmunologic Reactions 15.3 Transfusion-Transmitted Diseases
16 Apheresis & Extracorporeal Circulation
16.1 Therapeutic Apheresis 16.2 Extracorporeal Circulation
17 Quality, Safety, Math & Instrumentation
17.1 Quality Assessment & Troubleshooting 17.2 Laboratory Safety 17.3 Laboratory Mathematics 17.4 Instrumentation
18 Laboratory Administration (SBB Only)
18.1 Financial Management 18.2 Operations & Information Technology 18.3 Personnel, Education & Training 18.4 Quality Management, Risk & Tissue Management
14.2 Component Therapy
Key Takeaways Explain This Topic AI
One apheresis platelet unit (or an equivalent pool of 4-6 whole-blood-derived units) is expected to raise an average adult's platelet count by roughly 30-60 x10^9/L absent ongoing consumption.
A corrected count increment (CCI) persistently below about 5,000-7,500 at 1 hour post-transfusion signals platelet refractoriness and should trigger investigation for immune (HLA/HPA antibody) versus nonimmune (fever, DIC, splenomegaly, sepsis) causes.
Irradiation prevents transfusion-associated graft-versus-host disease and is required for HSCT recipients, purine-analog chemotherapy recipients, intrauterine transfusion, and directed donations from blood relatives, among other high-risk groups.
Washing removes residual donor plasma proteins for patients with recurrent severe allergic reactions or IgA deficiency with anti-IgA; it is a different fix from leukoreduction, which targets febrile reactions, HLA alloimmunization, and CMV transmission risk.
Plasma is dosed at roughly 10-15 mL/kg to raise factor levels about 20-30%, and cryoprecipitate is dosed to target a fibrinogen rise, commonly using a pool of 4-6 units in a bleeding patient with hypofibrinogenemia.
Last updated: July 2026
Matching the component to the defect
Component therapy questions on the SBB exam usually present a clinical deficit and ask which product, and which modification of that product, fixes it. The starting logic never changes: red cells restore oxygen-carrying capacity, platelets restore platelet number or function, plasma restores multiple coagulation factors, and cryoprecipitate restores fibrinogen and a narrow set of other factors.
- Clinical deficit Best product Common trap
- Symptomatic anemia or acute blood loss Red blood cells Plasma does not correct anemia
Thrombocytopenia or platelet dysfunction with bleeding/procedure need Platelets Red cells do not correct platelet count
Multiple coagulation factor deficiency with bleeding or urgent reversal Plasma (or factor concentrate/PCC per policy) Plasma is not a volume expander
Hypofibrinogenemia with bleeding (obstetric hemorrhage, DIC, trauma) Cryoprecipitate (or fibrinogen concentrate) Platelets do not replace fibrinogen
Severe neutropenia with refractory bacterial/fungal sepsis unresponsive to antibiotics Granulocytes (rare, time-sensitive) Granulocytes are not a substitute for antimicrobial therapy
Dosing and expected response
Quantifying the expected response is what separates specialist-level questions from generalist ones.
Red blood cells. One adult RBC unit (roughly 250-300 mL) is expected to raise hemoglobin approximately 1 g/dL (hematocrit approximately 3%) in an average-sized adult without ongoing loss. A rise smaller than expected after appropriate dosing should prompt investigation for occult bleeding, hemolysis, or a dilutional/consumptive process, not simply another unit ordered reflexively.
Platelets. A single apheresis platelet unit contains roughly 3 x10^11 platelets and is the dose-equivalent of pooling 4-6 whole-blood-derived (random-donor) platelet units. In an average adult without ongoing consumption, this dose raises the platelet count by roughly 30-60 x10^9/L. When the response is inadequate, calculate the corrected count increment (CCI) : CCI = ( post-transfusion count − pre-transfusion count ) × BSA (m 2 ) platelets transfused × 10 11 \text{CCI} = \frac{(\text{post-transfusion count} - \text{pre-transfusion count}) \times \text{BSA (m}^2\text{)}}{\text{platelets transfused} \times 10^{11}} CCI = platelets transfused × 1 0 11 ( post-transfusion count − pre-transfusion count ) × BSA (m 2 )
A CCI below roughly 5,000-7,500 at 1 hour , or below roughly 4,500 at 18-24 hours , on repeated ABO-compatible transfusions defines platelet refractoriness . The exam expects you to split the differential: immune causes (HLA Class I alloantibodies, less commonly HPA alloantibodies) versus nonimmune causes (fever, sepsis, DIC, splenomegaly, amphotericin B, some antibiotics). Immune refractoriness is managed with HLA-matched or crossmatch-compatible platelets; nonimmune causes are managed by treating the underlying consumptive process.
Plasma. Typical dosing is 10-15 mL/kg , which raises most coagulation factor levels by roughly 20-30% — generally enough to support hemostasis for factors with a hemostatic threshold in that range.
Cryoprecipitate. Dosing targets a fibrinogen increase; a standard pool (commonly 4-6 units, or an equivalent pathogen-reduced pooled product) is a typical adult dose for hypofibrinogenemic bleeding, with the exact rise dependent on baseline fibrinogen, plasma volume, and consumption.
Special processing and modifications
Modifications solve specific problems — they are not interchangeable, and the exam tests that distinction directly.
Modification Purpose Key indications
Irradiation Prevents transfusion-associated graft-versus-host disease by inactivating donor lymphocytes HSCT recipients, intrauterine transfusion, congenital cellular immunodeficiency, purine-analog chemotherapy (e.g., fludarabine), directed donations from blood relatives, HLA-matched/crossmatched platelets
Leukoreduction Removes most donor white cells Reduces febrile nonhemolytic reactions, HLA alloimmunization, and CMV transmission risk; increasingly performed pre-storage as a universal practice
Washing Removes residual donor plasma proteins Recurrent severe/anaphylactic allergic reactions, IgA deficiency with anti-IgA, neonatal exchange transfusion
CMV-seronegative selection Provides serologically CMV-negative product Alternative or adjunct to leukoreduction for intrauterine transfusion, low-birth-weight neonates, CMV-negative pregnant patients, and CMV-negative transplant candidates
Volume reduction Concentrates the product into a smaller volume Neonates and patients with cardiac or renal compromise who cannot tolerate standard volumes
Frozen deglycerolized RBCs Extends storage of rare phenotypes Preserves rare units for years frozen; requires deglycerolization and has a short post-processing outdate (commonly 24 hours in an open system)
A frequent exam trap: leukoreduction and washing are not interchangeable . Leukoreduction removes white cells and lowers febrile/HLA/CMV risk; it does not meaningfully remove plasma proteins, so it will not fix a severe allergic reaction. Washing removes plasma proteins but is not a validated substitute for irradiation against graft-versus-host disease.
Massive transfusion component strategy
Beyond individual dosing, mass-casualty and major hemorrhage settings increasingly use ratio-based component therapy (near 1:1:1 RBC:plasma:platelet) or low-titer group O whole blood (LTOWB) where available, both intended to approximate the composition of whole blood and limit dilutional coagulopathy, before transitioning to viscoelastic-guided (TEG/ROTEM) targeted component replacement once results are available.
Newer platelet processing: additive solution and pathogen reduction
Two processing trends show up increasingly on specialist-level exams. Platelet additive solution (PAS) replaces most of the donor plasma surrounding apheresis platelets with a nutrient/buffer solution, which reduces plasma-protein exposure (lowering allergic and febrile reaction rates) while preserving platelet count and function — a distinct mechanism from washing, which is performed on demand rather than at collection. Pathogen-reduction technology (for example, amotosalen/UV or riboflavin/UV treatment) inactivates residual white cells, bacteria, and many viruses in platelets and plasma; in some jurisdictions a validated pathogen-reduction step is accepted in place of routine bacterial culture and, in certain systems, in place of gamma irradiation for GVHD prevention specifically in that treated component. The exam expects you to recognize pathogen reduction as a distinct safety strategy from irradiation and leukoreduction, not a universal replacement for every modification.
Granulocyte concentrates
Granulocyte transfusion is a narrow, time-critical therapy reserved for severely neutropenic patients with bacterial or fungal infection that is progressing despite appropriate antimicrobial therapy, most often in the setting of anticipated marrow recovery (post-chemotherapy or post-transplant). Donors are typically mobilized with corticosteroids or growth factor (G-CSF) to increase collection yield. Because the product's entire value is its white cell content, granulocytes are never leukoreduced , are always irradiated to prevent GVHD from the very high lymphocyte content, and must be transfused as soon as possible after collection since granulocyte function declines rapidly during storage.